検索結果一覧

ポスター / Poster

ポスター 9 (Poster 9) :CML:臨床1 (CML:Clinical Research 1)
 
日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
田中 英夫 (Hideo Tanaka):1
1:広島市立安佐市民病院 血液内科

前へ戻る


Ponatinib in Philadelphia chromosome-positive (Ph+) leukemias: Results of the phase 2 PACE trial

演題番号 : PS-1-59

Jorge E Cortes:1、Dong-Wook Kim:2、Javier Pinilla-Ibarz:3、Philipp le Coutre:4、Ronald Paquette:5、Charles Chuah:6、Franck E Nicolini:7、Jane Apperley:8、H Jean Khoury:9、Moshe Talpaz:10、John DiPersio:11、Daniel DeAngelo:12、Elisabetta Abruzzese:13、Delphine Rea:14、Michele Baccarani:15、Martin C Müller:16、Carlo Gambacorti-Passerini:17、Stephanie Lustgarten:18、Victor M Rivera:18、Tim Clackson:18、Christopher D Turner:18、Frank G Haluska:18、Francois Guilhot:19、Michael W Deininger:20、Andreas Hochhaus:21、Timothy Hughes:22、John M Goldman:8、Neil Shah:23、Hagop Kantarjian:1

1:The University of Texas MD Anderson Cancer Center, Houston, TX, USA、2:Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea、3:H. Lee Moffitt Cancer Center, Tampa, FL, USA、4:Charité-Universitätsmedizin Berlin, Berlin, Germany、5:Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA, USA、6:Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore、7:Centre Hospitalier Lyon Sud, Pierre Benite, France、8:Imperial College London, London, UK、9:Emory Winship Cancer Institute, Atlanta, GA, USA、10:Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA、11:Washington University School of Medicine, St Louis, MO, USA、12:Dana-Farber Cancer Institute, Boston, MA, USA、13:Ospedale S. Eugenio, Rome, Italy、14:Service des Maladies du Sang, Hopital Saint-Louis, Paris, France、15:S Orsola-Malpighi University Hospital, Bologna, Italy、16:III. Med. Klinik, Universitätsmedizin Mannheim, Mannheim, Germany、17:Unità di Ricerca Clinica - Ematologia, Azienda Ospedaliera San Gerardo/University of Milano Bicocca, Monza, Italy、18:ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA、19:CIC Inserm 0802, CHU de Poitiers, France、20:Huntsman Cancer Institute University of Utah, Salt Lake City, UT USA、21:Universitätsklinikum Jena, Jena, Germany、22:Institute of Medicine and Veterinary Science, Adelaide, Australia、23:University of California San Francisco, San Francisco, CA, USA

Ponatinib in Philadelphia chromosome-positive (Ph+) leukemias: Results of the phase 2 PACE trial

Effect of graft sources on allo-SCT outcome in adults with CML in the era of Imatinib

演題番号 : PS-1-60

大橋 一輝 (Kazuteru Ohashi):1、長村 登紀子 (Tokiko Nagamura-Inoue):2、長村 文孝 (Fumitaka Nagamura):3、東條 有伸 (Arinobu Tojo):4、宮村 耕一 (Koichi Miyamura):5、石川 淳 (Jun Ishikawa):6、森島 泰雄 (Yasuo Morishima):7、森 毅彦 (Takehiko Mori):8、熱田 由子 (Yoshiko Atsuta):9、坂巻 壽 (Hisashi Sakamaki):1

1:Hematology Division, Tokyo Metro Komagome Hospital、2:Department of Cell Processing/Transfusion, Research Hospital, The Institute of Medical Science, The University of Tokyo、3:Division of Clinical Trial Safety Management, Research Hospital, The Institute of Medical Science, The University of Tokyo、4:Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo、5:Department of Hematology, Japanese Red Cross Nagoya Daiichi Hospital、6:Hematology&Oncology,Osaka Medical center for cancer and cardiovascular diseases、7:Division of Epidemiology/Prevention, Aichi Cancer Center Research Institute、8:Division of Hematology, Department of Medicine, Keio University School of Medicine、9:Department of HSCT Data Management / Biostatistics, Nagoya University Graduate School of Medicine

Effect of graft sources on allo-SCT outcome in adults with CML in the era of Imatinib

Preliminary report of a phase 1/2 study of ponatinib in Japanese patients with Ph+ Leukemias

演題番号 : PS-1-61

Tetsuzo Tauchi:1、Arinobu Tojo:2、中前 博久 (Hirohisa Nakamae):3、小林 幸夫 (Yukio Kobayashi):4、Shinichiro Okamoto:5、宮村 耕一 (Koichi Miyamura):6、許 泰一 (Taiichi Kyo):7、岩崎 浩己 (Hiromi Iwasaki):8、畠 清彦 (Kiyohiko Hatake):9、Noriko Usui:10、Narayana I Narasimhan:11、Simin Hu:11、Kumiko Yanase:11、Joshua Zhang:11、直江 知樹 (Tomoki Naoe):12、Kazuma Ohyashiki:1

1:Tokyo Medical University Hospital, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan、2:The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan、3:Osaka City University Hospital, Osaka City University, Osaka-shi, Osaka, Japan、4:National Cancer Center Hospital, Chuo-ku, Tokyo, Japan、5:Keio University Hospital, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan、6:Japan Red Cross Nagoya Daiichi Hospital, Nagoya-shi, Aichi, Japan、7:Hiroshima Red Cross and Atomic Bomb Survivors Hospital, Naka-ku, Hiroshima, Japan、8:Kyushu University Hospital, Kyushu University, Higashi-ku Fukuoka, Japan、9:Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan、10:Jikei University Daisan Hospital, Komae-shi, Tokyo, Japan、11:ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA、12:Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan

Preliminary report of a phase 1/2 study of ponatinib in Japanese patients with Ph+ Leukemias

Characteristics of patients with chronic myeloid leukemia and treatment outcomes at our institution

演題番号 : PS-1-62

飯野 昌樹 (Masaki Iino):1

1:Dept. of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan、2:Ambulatory Therapeutic Cancer Center, Yamanashi Prefectural Central Hospital, Kofu, Japan

Characteristics of patients with chronic myeloid leukemia and treatment outcomes at our institution

Long-term outcome of imatinib therapy for patients with chronic myeloid leukemia in single institute

演題番号 : PS-1-63

瀧本 円 (Madoka Takimoto):1、小川 考平 (Kohei Ogawa):1、横井 聡 (Satoshi Yokoi):1、佐野 文明 (Fumiaki Sano):1、三浦 偉久男 (Ikuo Miura):2

1:Int. Med, Hematology, Yokohama City Seibu Hospital, St. Marianna Univ、2:Department of Internal Medicine, Division of Hematology,St. Marianna University School of Medicine

Long-term outcome of imatinib therapy for patients with chronic myeloid leukemia in single institute

Muscle cramps as the low-grade adverse events of imatinib improved with changes to nilotinib

演題番号 : PS-1-64

加藤 裕一 (Yuichi Kato):1、塩野 洋介 (Yosuke Shiono):1、鈴木 郁子 (Ikuko Suzuki):1、高野 桂 (Kei Kohno):1、加藤 丈夫 (Takeo Kato):1

1:Department of Hematology, Yamagata University, Japan

Muscle cramps as the low-grade adverse events of imatinib improved with changes to nilotinib

Comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

演題番号 : PS-1-65

植村 麻希子 (Makiko Uemura):1、今滝 修 (Osamu Imataki):1、河内 康憲 (Yasunori Kawachi):2,3、福本 哲也 (Tetsuya Fukumoto):3、井出 眞 (Makoto Ide):3、大西 宏明 (Hiroaki Onishi):3、川上 公宏 (Kimihiro Kawakami):4、脇 正人 (Masato Waki):4、星島 康男 (Yasuo Hoshijima):5、松岡 亮仁 (Akihito Matsuoka):6、田岡 輝久 (Teruhisa Taoka):6、黒井 大雅 (Taiga Kuroi):7、岩井 艶子 (Tsuyako Iwai):8、横倉 繁行 (Shigeyuki Yokokura):1、新谷 高理 (Takamichi Shintani):1、脇 房子 (Fusako Waki):1、松本 謙介 (Kensuke Matsumoto):1、松永 卓也 (Takuya Matsunaga):1

1:Division of Hematology, Kagawa University, Kagawa, Japan、2:Department of Internal Medicine, Division of Hematology, Kaisei General Hospital, Kagawa, Japan、3:Department of Internal Medicine, Division of Hematology, Takamatsu Red Cross Hospital, Kagawa, Japan、4:Department of Internal Medicine, Division of Hematology, Kagawa Prefectural Central Hospital, Kagawa, Japan、5:Department of Internal Medicine, Division of Hematology, Takamatsu Municipal Hospital, Kagawa, Japan、6:Department of Internal Medicine, Division of Hematology, Sakaide City Hospital, Kagawa, Japan、7:Department of Internal Medicine, Division of Hematology, KKR Takamatsu Hospital, Kagawa, Japan、8:Department of Pediatrics, Division of pediatric oncology, Kagawa National Children's Hospital, Kagawa, Japan

Comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

Long term efficacy and safety of imatinib in elderly patients with CML-CP

演題番号 : PS-1-66

赤木 智昭 (Tomoaki Akagi):1、山本 豊 (Yutaka Yamamoto):1、山口 公平 (Kouhei Yamaguchi):1、久保 恒明 (Koumei Kubo):1

1:Dept. of Haematol., Aomori Prefectural Central Hospital, Japan

Long term efficacy and safety of imatinib in elderly patients with CML-CP